Entera Bio

Entera Bio CapEx Growth

The Year-over-Year CapEx Growth of Entera Bio (ENTX) as of Nov 22, 2026 is 3,466.67 %. In the previous year, Year-over-Year CapEx Growth was -82.35 % — a change of -4,309.52% (higher).

CapEx Growth

3,466.67 %

YoY

-4,309.52%

Last updated:

Year-over-Year CapEx Growth of Entera Bio is 2025 3,466.67 % . Year-over-Year CapEx Growth of Entera Bio was 2024 -82.35 % . It decreases by -4,309.52% higher compared to the previous year.

The Entera Bio CapEx Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx Growth
Date
CapEx Growth
Jan 1, 2018
33.33 USD
Jan 1, 2019
-41.18 USD
Jan 1, 2020
32.50 USD
Jan 1, 2021
-67.92 USD
Jan 1, 2022
176.46 USD
Jan 1, 2023
-63.83 USD
Jan 1, 2024
-82.35 USD
Jan 1, 2025
3,466.67 USD
The Entera Bio CapEx Growth history
YEARCapEx GrowthYoY
3,466.67 %-4,309.52%
-82.35 %+29.02%
-63.83 %-136.17%
176.46 %-359.80%
-67.92 %-309.00%
32.50 %-178.93%
-41.18 %-223.53%
33.33 %+36.67%
24.39 %-201.31%
-24.07 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Entera Bio Stock analysis

What does Entera Bio do? Entera Bio Ltd is an emerging biotechnology company focused on developing oral medications to treat unmet medical needs. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Its history began with the discovery of the "EnteraGam" molecule in the intestinal cells of breastfed infants, which helps them fight infections. This led to the development of EnteraGam for the treatment of various autoimmune diseases. The company's business model is based on developing oral formulations for existing drugs and discovering and developing new molecules. Its focus areas are osteoporosis, hypoparathyroidism, chronic kidney disease, and autoimmune diseases. Entera Bio is divided into three business divisions: the Oral Protein Delivery Platform, the Oral Parathyroid Hormone (PTH) Platform, and the Collagen-based Platform for Wound Healing. Its products include EB611, a candidate for hypoparathyroidism treatment, EB613 for osteoporosis treatment, and EB612 for chronic kidney disease. These products have potential to improve the lives of millions of patients worldwide. Entera Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entera Bio stock

Year-over-Year CapEx Growth of Entera Bio is 3,466.67 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year CapEx Growth Entera Bio since 2006 – with annual values, charts, and detailed analysis.

CapEx growth measures the percentage change in capital expenditures. Increasing CapEx can signal investment in future growth capacity.

To evaluate Year-over-Year CapEx Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year CapEx Growth.

Year-over-Year CapEx Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year CapEx Growth's Entera Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Entera Bio

All Key Metrics — Entera Bio